Disability News and Research

RSS

Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS

Genzyme Corp., a subsidiary of sanofi-aventis Group, today reported additional five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial showing that nearly two-thirds of alemtuzumab treated patients remained free of clinically-active disease as much as four years after most patients received their last course of the investigational drug.

15 Apr 2011

Cerapedics announces i-FACTOR biologic bone graft study results in PLIF spine surgery

Cerapedics, Inc., a medical device company focused on developing and commercializing novel osteobiologic products, announced the results of a prospective, randomized, controlled trial of its i-FACTOR biologic bone graft for patients undergoing posterior lumbar interbody fusion spine procedures.

12 Apr 2011

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Teva Pharmaceutical Industries Ltd. today announced that several new studies further support the efficacy and safety of the company's innovative central nervous system products.

12 Apr 2011

Experts to discuss latest findings in IBD research at Rome meeting

Experts from 11 countries will gather this week in Rome to discuss innovative strategies for studying and treating Inflammatory Bowel Diseases.

12 Apr 2011

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today results from the two-year Phase III ALLEGRO study of laquinimod, an oral, once-daily, investigational immunomodulator for the treatment of relapsing forms of multiple sclerosis (MS). These data will be presented as late-breaking research at the Annual Meeting of the American Academy of Neurology (AAN).

12 Apr 2011

Laquinimod drug greatly reduces number of relapses in patients with MS

The drug laquinimod reduced the number of relapses for people with multiple sclerosis, in a large, long-term Phase III clinical study that will be presented as late-breaking research at the 63rd Annual Meeting of the American Academy of Neurology, April 9-16, 2011, in Honolulu.

12 Apr 2011

Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS

Biogen Idec announced today positive top-line results from DEFINE, the first of two pivotal Phase 3 clinical trials designed to evaluate the investigational oral compound BG-12 as a monotherapy in people with relapsing-remitting multiple sclerosis.

11 Apr 2011

Gilenya can reduce risk of disability progression in patients with RRMS

A new analysis demonstrated that Gilenya reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis, regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology.

11 Apr 2011

New survey to understand patterns of disability and aging in older Americans

Researchers at the Johns Hopkins Bloomberg School of Public Health have been selected to lead a new national survey of older Americans to understand patterns of disability and aging.

11 Apr 2011

Survivors of severe critical illness requiring intensive care do not regain physical or psychological health

A unique and richly detailed long-term study of survivors of severe critical illness requiring intensive care found that even those who were previously healthy, young and working did not regain the physical or psychological health they had before their illness.

8 Apr 2011

Vascular Disease Foundation invites applicants for ambassador program

If you or someone you love have been affected by vascular disease and have a willingness to help others, the Vascular Disease Foundation (VDF) is calling for applications to join its ambassador program to help promote vascular disease awareness.

8 Apr 2011

Small businesses can benefit from high-quality employee wellness programs

A new study published today supports the premise that high-quality employee wellness programs in small businesses improve employee health and well-being, which drives improvements in organizational outcomes such as absenteeism, healthcare costs and disability claims.

8 Apr 2011

Antidepressant medication improves physical recovery from stroke

A University of Iowa study finds that patients treated with a short course of antidepressants after a stroke have significantly greater improvement in physical recovery than patients treated with a placebo. Moreover, the study is the first to demonstrate that this physical recovery continues to improve for at least nine months after the antidepressant medication is stopped.

8 Apr 2011

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

Genzyme, a subsidiary of sanofi-aventis Group, announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis at the American Academy of Neurology's 63rd Annual Meeting in Hawaii, April 9 - 16, 2011.

8 Apr 2011

Study: DBS surgery allows 77% of patients to stop anti-tremor medication use

Deep brain stimulation, a surgical procedure to suppress faulty nerve signals, allowed 77 percent of patients to stop the medications used to treat their essential tremors within one year following the surgery, University of South Florida researchers report.

8 Apr 2011

Patients with stroke can benefit from antidepressants

8 Apr 2011

New Pipeline Embolization Device receives FDA approval for treatment of brain aneurysms

The U.S. Food and Drug Administration today approved a new device that provides neurointerventional surgeons with another tool to treat brain aneurysms without performing open surgery.

7 Apr 2011

Work, social and family disability affect 50% of patients with bipolar disorder

Such was the conclusion obtained in a study conducted at the University of Granada that was recently awarded a prize in the IV Spain-Portugal Meeting on Therapeutical Adherence held in Oporto.

6 Apr 2011

Socioeconomic factors still influence autism diagnosis

While there is an increasing equality in terms of the likelihood that children from communities and families across the socioeconomic spectrum will be diagnosed with autism, a new study finds that such factors still influence the chance of an autism diagnosis, though to a much lesser extent than they did at the height of rising prevalence.

6 Apr 2011

New medical guidelines for diabetes care

Today the American Association of Clinical Endocrinologists released new medical guidelines for developing comprehensive care plan for management of diabetes mellitus.

6 Apr 2011